1. Academic Validation
  2. NF-κB inhibition attenuates sympathetic hyperreflexia and concomitant development of autonomic dysreflexia and immune dysfunction after spinal cord injury

NF-κB inhibition attenuates sympathetic hyperreflexia and concomitant development of autonomic dysreflexia and immune dysfunction after spinal cord injury

  • Commun Biol. 2025 May 22;8(1):787. doi: 10.1038/s42003-025-08237-y.
Micaela L O'Reilly 1 Mariah J Wulf 1 Theresa M Connors 1 Ying Jin 1 Frank Bearoff 2 Nan Hai 3 Julien Bouyer 1 Sandhya Kortagere 4 Yinghui Zhong 3 John R Bethea 5 Veronica J Tom 6
Affiliations

Affiliations

  • 1 Department of Neurobiology and Anatomy, Marion Murray Spinal Cord Research Center, Drexel University College of Medicine, Philadelphia, PA, USA.
  • 2 Department of Neurology, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA.
  • 3 School of Biomedical Engineering Science and Health Systems, Drexel University, Philadelphia, PA, USA.
  • 4 Department of Microbiology & Immunology, Drexel University College of Medicine, Philadelphia, PA, USA.
  • 5 Department of Anatomy and Cell Biology, George Washington University, Washington, DC, USA.
  • 6 Department of Neurobiology and Anatomy, Marion Murray Spinal Cord Research Center, Drexel University College of Medicine, Philadelphia, PA, USA. vjt25@drexel.edu.
Abstract

Heightened sympathetic reflexes (sympathetic hyperreflexia, SH) post-high-level spinal cord injury (SCI) detrimentally impact effector organs, resulting in peripheral immune dysfunction and Cardiovascular Disease, two leading causes of morbidity and mortality in SCI. We previously found that an activated neuroimmune system after SCI contributes to intraspinal plasticity in the spinal sympathetic reflex (SSR) circuit, underlying SH. We hypothesize that activation of NF-κB, a key regulator of inflammation, in spinal cord below-SCI contributes to driving SSR circuit plasticity, resulting in SH-associated autonomic dysreflexia (AD) and peripheral immune dysfunction. Here, we demonstrate inhibition of central NF-κB signaling via intrathecal delivery of dimethylamino parthenolide (DMAPT) significantly decreases SH post-complete transection of thoracic spinal segment 3 in adult rats. This included reduced AD severity that was associated with decreased interneuron recruitment into the SSR circuit after SCI. We also observed intrathecal DMAPT-treatment improved survival post-SCI that corresponded with normalized numbers of splenic regulatory T-cells. These findings underscore central NF-κB signaling as a key component driving SH after SCI.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-16172
    ≥98.0%, NF-κB Inhibitor